Chengda Pharmaceuticals Co (SZSE:301201) Net Income From Continuing Operations : ¥90.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Chengda Pharmaceuticals Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Chengda Pharmaceuticals Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥18.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥90.2 Mil.

Chengda Pharmaceuticals Co Net Income From Continuing Operations Historical Data

The historical data trend for Chengda Pharmaceuticals Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengda Pharmaceuticals Co Net Income From Continuing Operations Chart

Chengda Pharmaceuticals Co Annual Data

Trend

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

54.19

119.61

100.27

106.48

91.10

Chengda Pharmaceuticals Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															19.62	9.79	31.86	29.83	18.73

Chengda Pharmaceuticals Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥90.2 Mil.

Chengda Pharmaceuticals Co (SZSE:301201) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chengda Pharmaceuticals Co Ltd (SZSE:301201) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100

Website

http://www.chengdapharm.com

Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.

Chengda Pharmaceuticals Co (SZSE:301201) Headlines

No Headlines